Royal Treatment

Scientists in the U.K. will sequence the genome of King Richard III.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, BRITISH SCHOOLThe remains of King Richard III, who died in 1485, were discovered beneath a parking lot in Leicester, U.K., in 2012, and their identity was confirmed last year. According to BBC News, the king’s final resting place has since been the subject of a legal battle. Before the medieval British monarch is reinterred, scientists from the University of Leicester are collecting bone samples from which to extract DNA, in the hopes of sequencing Richard III’s genome. The scientists will also sequence the genome of one of his living descendants, according to a Wellcome Trust statement.

“It is an extremely rare occurrence that archaeologists are involved in the excavation of a known individual, let alone a king of England,” the university’s Turi King, who is leading the project, said in the statement. “At the same time we are in the midst of a new age of genetic research, with the ability to sequence entire genomes from ancient individuals and, with them, those of pathogens that may have caused infectious disease.”

“The idea is that this will become a resource for people to look at,” King told the Los Angeles Times. As The Guardian noted, King told reporters that, once it’s complete, she and her colleagues plan to deposit Richard III’s genome sequence in a publicly accessible archive.

“We’re still in the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies